Analysis on short-term change of macular function and the correlates after intravitreal conbercept for CRVO-ME

BMC Ophthalmol. 2022 Apr 8;22(1):162. doi: 10.1186/s12886-022-02381-3.

Abstract

Aim: To study the short-term change of macular function and the correlates after intravitreal conbercept for CRVO-ME.

Study design: Prospective, clinical study.

Methods: Twenty Three patients(23 eyes) were recruited, who were non-ischemia central retinal vein occlusion diagnosed by FFA (fundus fluorescein angiography) and treated with intravitreal conbercept for macular edema, best - corrected visual acuity ( BCVA), central macular thickness(CMT), amplitude density of P1 wave and implicit time of P1,N1 wave from ring 1 and ring 2 of mf-ERG were measured before and 1 week、2 month after treatment.

Results: Compared to the baseline, BCVA、CMT、amplitude density of P1 wave and implicit time of P1,N1 wave from ring 1 and ring 2 were greatly improved at 1 W、2 M after treatment; better results were gained at 2 M compared to 1 W; Pearson correlation analysis shows no significantly correlation between the improvement of mf-ERG with the change of BCVA、CMT.

Conclusion: The BCVA、the structure and the function of macular were greatly improved after intravitreal conbercept for central retinal vein occlusion induced macular edema; however no significantly correlation between the improvement of the function of macular with the strcture of macular and BCVA.

Keywords: Conbercept; Macular edema; Multifocal electroretinogram; Non-ischemia central retinal vein occlusion; Optical coherence tomography.

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Fluorescein Angiography
  • Humans
  • Intravitreal Injections
  • Macular Edema* / diagnosis
  • Macular Edema* / drug therapy
  • Macular Edema* / etiology
  • Prospective Studies
  • Recombinant Fusion Proteins
  • Retinal Vein Occlusion* / diagnosis
  • Retinal Vein Occlusion* / drug therapy
  • Tomography, Optical Coherence / methods
  • Treatment Outcome
  • Visual Acuity

Substances

  • Angiogenesis Inhibitors
  • Recombinant Fusion Proteins
  • KH902 fusion protein